Why Did INBS Stock Fall 17% Today? Intelligent Bio Solutions announced a 1-for-10 reverse stock split on Friday to regain listing compliance.
Intelligent Bio Solutions Stock Rises On New Contract For Drug Testing Technology The new customer account represents one of INBS's most significant UK commercial deployments to date, the company said.
Which stocks are experiencing notable movement on Wednesday? Stay up-to-date with the latest market trends in the middle of the day on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Wednesday's session: gap up and gap down stocks Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
EXCLUSIVE: Intelligent Bio Expects Double Digit Topline Growth In Q4 Intelligent Bio forecasts 16% revenue growth for Q4 2025 and strengthens FDA filing with new data as it expands global reach and system capabilities.
EXCLUSIVE: Intelligent Bio Solutions' New Data Confirms Ability To Detect Trace Sweat Volumes At Ultra-Micro Level Intelligent Bio strengthens its FDA 510(k) submission with new data, cybersecurity tests, and advanced fingerprint sweat analysis technology.
EXCLUSIVE: Intelligent Bio Targets Global Market With Distribution Pact For Sweat-Based Drug Detection Patch Intelligent Bio expands global reach with SMARTOX deal to distribute its sweat-based drug detection patch across markets outside the U.S. and Canada.
EXCLUSIVE: Intelligent Bio's Fingerprint Drug Testing Gains Momentum With New Australian Rollout Intelligent Bio Solutions expands into environmental services as Managed Waste Service rolls out its drug testing system across New South Wales sites.
Intelligent Bio Rises On Partnership With Smartox To Expand US Market Presence: Retail Hopes The Stock To Hit $2.6 Intelligent Bio is actively pursuing FDA clearance for its opiate test system for codeine, utilizing its fingerprint sweat-based testing technology.
EXCLUSIVE: Intelligent Bio Solutions Expands US Forensic Market Presence, Seeks FDA Clearance For Fingerprint Drug Testing Intelligent Bio grows U.S. forensic market presence via SMARTOX, with 7,000+ tests run and FDA clearance underway for wider market entry.
EXCLUSIVE: Intelligent Bio Solutions Q3 Gross Profit Jumps By 91% Intelligent Bio Solutions reported a Q3 loss of 44 cents per share with a 20% revenue rise from Q2 and 91% year-over-year gross profit growth.
EXCLUSIVE: Intelligent Bio Solutions Adds Sixth US Patent For Its Drug Screening Technology Intelligent Bio Solutions (INBS) received a U.S. patent for its fingerprint drug screening technology, expanding its intellectual property portfolio.
EXCLUSIVE: FDA Seeks Additional Information For Intelligent Bio Solutions' Drug Screening System, Clearance Process Remains on Track For 2025 US Launch Intelligent Bio Solutions awaits FDA clearance for its fingerprint drug test, aiming for a 2025 U.S. launch and expanding its presence in the multi-billion market.
